Initiation of high frequency multi-drug resistance following kinase targeting by siRNAs

Cell Cycle

Volumn 6, Issue 16, 2007, Pages 2001-2004

  Swanton, Charles ^a,b   Nicke, Barbara ^a   Marani, Michela ^a   Kelly, Gavin ^a   Downward, Julian ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

5 FU; Cisplatin; Doxorubicin; Kinome; Multi drug resistance; Non cross resistance; Paclitaxel; RNA interference; siRNA

Indexed keywords

ABC TRANSPORTER; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; PACLITAXEL; PHOSPHOTRANSFERASE; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CANCER CENTER; CANCER SURVIVAL; CONTROLLED STUDY; CROSS RESISTANCE; DRUG MECHANISM; DRUG RESPONSE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; PROTEIN TARGETING; QUALITY OF LIFE; RNA INTERFERENCE; SOLID TUMOR;

EID: 34548279988     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6.16.4538     Document Type: Article

References (14)

1. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22:229-37.
2. Gore M, Preston N, A'Hern R, Hill C, Mitchell P, Chang J, et al. Platinum-Taxol non-cross resistance in epithelial ovarian cancer. Br J Cancer 1995; 71:1308-10.
3. Gore M, Rustin G, Slevin M, Gallagher C, Penson R, Osborne R, et al. Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. Br J Cancer 1997; 75:710-4.
4. Johnston S, Swanton C. Handbook of metastatic breast cancer. 1st ed. Taylor and Francis, 2006.
5. Bria E, Nistico C, Cuppone F, Carlini P, Ciccarese M, Milella M, et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: Pooled analysis of 15,500 patients. Cancer 2006; 106:2337-44.
6. Bookman MA. GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-liposomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial (EOC) or primary peritoneal carcinoma (PPC). 2006 ASCO Annual Meeting Proceedings Part 1, 2006.
7. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5:219-34.
8. Blagosklonny MV. Why therapeutic response may not prolong the life of a cancer patient: Selection for oncogenic resistance. Cell Cycle 2005; 4:1693-8.
9. Swanton C, Marani M, Pardo O, Warne P, Sahai E, Elustondo F, et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007; 11:498-512.
10. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005; 205:275-92.
11. MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 2005; 7:591-600.
12. Glasspool RM, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 2006; 94:1087-92.
13. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: The multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92:1295-302.
14. Duesberg P, Stindl R, Hehlmann R. Origin of multidrug resistance in cells with and without multidrug resistance genes: Chromosome reassortments catalyzed by aneuploidy. Proc Natl Acad Sci USA 2001; 98:11283-8.